GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003010018 | Esophagus | ESCC | regulation of endocytosis | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:004311218 | Esophagus | ESCC | receptor metabolic process | 104/8552 | 166/18723 | 7.44e-06 | 7.37e-05 | 104 |
GO:19038289 | Esophagus | ESCC | negative regulation of cellular protein localization | 76/8552 | 117/18723 | 1.97e-05 | 1.72e-04 | 76 |
GO:000689818 | Esophagus | ESCC | receptor-mediated endocytosis | 142/8552 | 244/18723 | 5.22e-05 | 4.05e-04 | 142 |
GO:004825916 | Esophagus | ESCC | regulation of receptor-mediated endocytosis | 66/8552 | 110/18723 | 1.72e-03 | 7.96e-03 | 66 |
GO:00360106 | Esophagus | ESCC | protein localization to endosome | 18/8552 | 24/18723 | 3.43e-03 | 1.41e-02 | 18 |
GO:003010016 | Oral cavity | OSCC | regulation of endocytosis | 121/7305 | 211/18723 | 4.74e-08 | 8.80e-07 | 121 |
GO:000689810 | Oral cavity | OSCC | receptor-mediated endocytosis | 125/7305 | 244/18723 | 6.56e-05 | 5.32e-04 | 125 |
GO:004311210 | Oral cavity | OSCC | receptor metabolic process | 88/7305 | 166/18723 | 1.68e-04 | 1.15e-03 | 88 |
GO:19038288 | Oral cavity | OSCC | negative regulation of cellular protein localization | 65/7305 | 117/18723 | 2.05e-04 | 1.36e-03 | 65 |
GO:004825910 | Oral cavity | OSCC | regulation of receptor-mediated endocytosis | 58/7305 | 110/18723 | 2.37e-03 | 1.05e-02 | 58 |
GO:00360105 | Oral cavity | OSCC | protein localization to endosome | 16/7305 | 24/18723 | 5.63e-03 | 2.17e-02 | 16 |
GO:00316239 | Oral cavity | OSCC | receptor internalization | 56/7305 | 113/18723 | 1.44e-02 | 4.69e-02 | 56 |
GO:003010017 | Oral cavity | LP | regulation of endocytosis | 81/4623 | 211/18723 | 6.57e-06 | 1.29e-04 | 81 |
GO:190382813 | Oral cavity | LP | negative regulation of cellular protein localization | 49/4623 | 117/18723 | 3.18e-05 | 4.89e-04 | 49 |
GO:004311216 | Oral cavity | LP | receptor metabolic process | 64/4623 | 166/18723 | 5.00e-05 | 7.02e-04 | 64 |
GO:000689817 | Oral cavity | LP | receptor-mediated endocytosis | 87/4623 | 244/18723 | 7.83e-05 | 1.02e-03 | 87 |
GO:003601012 | Oral cavity | LP | protein localization to endosome | 14/4623 | 24/18723 | 4.52e-04 | 4.30e-03 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKRD13A | SNV | Missense_Mutation | | c.524G>T | p.Ser175Ile | p.S175I | Q8IZ07 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANKRD13A | SNV | Missense_Mutation | novel | c.967N>T | p.Thr323Ser | p.T323S | Q8IZ07 | protein_coding | tolerated(1) | benign(0.41) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ANKRD13A | insertion | Nonsense_Mutation | novel | c.1198_1199insGTGTGGAGTAAAGCTGCTGTTGTCTAGCCTACTGCAT | p.Lys400SerfsTer4 | p.K400Sfs*4 | Q8IZ07 | protein_coding | | | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ANKRD13A | insertion | Frame_Shift_Ins | novel | c.523_524insCTACT | p.Ser175ThrfsTer15 | p.S175Tfs*15 | Q8IZ07 | protein_coding | | | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANKRD13A | insertion | Frame_Shift_Ins | novel | c.1054_1055insGGTTAACACGTCCACCTCAGACACTGAGTGCC | p.Glu352GlyfsTer13 | p.E352Gfs*13 | Q8IZ07 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ANKRD13A | SNV | Missense_Mutation | novel | c.437N>A | p.Cys146Tyr | p.C146Y | Q8IZ07 | protein_coding | tolerated(1) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANKRD13A | SNV | Missense_Mutation | novel | c.631N>T | p.Leu211Phe | p.L211F | Q8IZ07 | protein_coding | tolerated(0.24) | possibly_damaging(0.757) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANKRD13A | SNV | Missense_Mutation | novel | c.886N>C | p.Asp296His | p.D296H | Q8IZ07 | protein_coding | tolerated(0.06) | probably_damaging(0.979) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
ANKRD13A | SNV | Missense_Mutation | rs769790065 | c.214N>T | p.Arg72Cys | p.R72C | Q8IZ07 | protein_coding | tolerated(0.19) | benign(0.001) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANKRD13A | SNV | Missense_Mutation | | c.629N>A | p.Arg210His | p.R210H | Q8IZ07 | protein_coding | tolerated(0.09) | benign(0.019) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |